GenCore version 5.1.3

OM protein - protein search, using sw model

Run on: January 13, 2003, 15:31:05 ; Search time 10.4014 Seconds
(without alignments)
596.865 Million cell updates/sec

Title: US-09-728-911-34
Perfect score: 1142
Sequence: 1 PEDPSDLLQHVKFQSSNFEN.....AKESAPYMCRVKTLPDRTWT 211

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 262574 seqs, 29422922 residues

Total number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_AA:*
1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep:*
2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep:*
3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep:*
4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep:*
5: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep:*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1142	100.0	574	2	US-08-906-713-2	Sequence 2, Appli
2	194.5	17.0	221	2	US-08-943-087-58	Sequence 58, Appl
3	192.5	16.9	221	2	US-08-943-087-56	Sequence 56, Appl
4	191.5	16.8	221	2	US-08-943-087-50	Sequence 50, Appl
5	191.5	16.8	553	2	US-08-943-087-2	Sequence 2, Appli
6	191.5	16.8	553	2	US-08-943-087-14	Sequence 14, Appl
7	191.5	16.8	553	2	US-08-943-087-16	Sequence 16, Appl
8	191.5	16.8	553	2	US-08-943-087-18	Sequence 18, Appl
9	191.5	16.8	553	2	US-08-943-087-20	Sequence 20, Appl
10	191.5	16.8	553	2	US-08-943-087-22	Sequence 22, Appl
11	191.5	16.8	553	2	US-08-943-087-24	Sequence 24, Appl
12	191.5	16.8	553	2	US-08-943-087-26	Sequence 26, Appl
13	191.5	16.8	553	2	US-08-943-087-28	Sequence 28, Appl
14	191.5	16.8	553	2	US-08-943-087-30	Sequence 30, Appl
15	191.5	16.8	553	2	US-08-943-087-32	Sequence 32, Appl
16	191.5	16.8	553	2	US-08-943-087-34	Sequence 34, Appl
17	191.5	16.8	553	2	US-08-943-087-36	Sequence 36, Appl
18	191.5	16.8	553	2	US-08-943-087-38	Sequence 38, Appl
19	191.5	16.8	553	2	US-08-943-087-40	Sequence 40, Appl
20	191.5	16.8	553	2	US-08-943-087-42	Sequence 42, Appl
21	191.5	16.8	553	2	US-08-943-087-44	Sequence 44, Appl
22	191.5	16.8	553	2	US-08-943-087-46	Sequence 46, Appl
23	191.5	16.8	553	2	US-08-943-087-48	Sequence 48, Appl
24	189.5	16.6	221	2	US-08-943-087-52	Sequence 52, Appl
25	189.5	16.6	221	2	US-08-943-087-54	Sequence 54, Appl
26	189	16.5	221	2	US-08-943-087-60	Sequence 60, Appl
27	143	12.5	559	1	US-08-424-788-3	Sequence 3, Appli
28	143	12.5	575	1	US-08-424-788-2	Sequence 2, Appli
29	143	12.5	575	1	US-08-110-683-4	Sequence 4, Appli
30	143	12.5	575	2	US-08-477-166-4	Sequence 4, Appli
31	143	12.5	575	2	US-08-472-097-4	Sequence 4, Appli
32	143	12.5	575	4	US-09-439-672-4	Sequence 4, Appli
33	143	12.5	575	5	PCT-US93-11638-4	Sequence 4, Appli
34	131.5	11.5	224	4	US-08-871-572B-9	Sequence 9, Appli
35	131.5	11.5	434	1	US-08-328-256-11	Sequence 11, Appl
36	131.5	11.5	436	2	US-08-307-588-2	Sequence 2, Appli
37	131.5	11.5	496	1	US-08-328-256-12	Sequence 12, Appl
38	131.5	11.5	557	1	US-08-328-256-10	Sequence 10, Appl
39	131.5	11.5	557	1	US-08-471-454-2	Sequence 2, Appli
40	131.5	11.5	557	2	US-08-466-974-2	Sequence 2, Appli
41	131.5	11.5	557	2	US-08-471-453-2	Sequence 2, Appli
42	131.5	11.5	557	2	US-08-307-588-4	Sequence 4, Appli
43	128.5	11.3	224	4	US-08-871-572B-13	Sequence 13, Appl
44	118	10.3	218	1	US-07-816-679A-3	Sequence 3, Appli
45	118	10.3	218	5	PCT-US92-11270-3	Sequence 3, Appli

ALIGNMENTS

RESULT 1
US-08-906-713-2
; Sequence 2, Application US/08906713
; Patent No. 5965704
; GENERAL INFORMATION:
; APPLICANT: Lok, Si
; APPLICANT: Adams, Robyn L.
; APPLICANT: Jelmberg, Anna C.
; APPLICANT: Whitmore, Theodore E.
; APPLICANT: Farrah, Theresa M.
; TITLE OF INVENTION: MAMMALIAN ZCYTOR11
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Zymogenetics
; STREET: 1201 Eastlake Ave East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/906,713
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Lunn, Paul G
; REGISTRATION NUMBER: 32,743
; REFERENCE/DOCKET NUMBER: 97-52
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6627
; TELEFAX: 206-442-6678
; TELEX:
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 574 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FRAGMENT TYPE: internal
US-08-906-713-2

Query Match 100.0%; Score 1142; DB 2; Length 574;

```
 Best Local Similarity   100.0%;  Pred. No. 5.1e-131;
 Matches  211;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 77

Qy      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      78 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

Qy     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 197

Qy     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
           |||||||||||||||||||||||||||||||
Db     198 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 228


RESULT 2
US-08-943-087-58
; Sequence 58, Application US/08943087
; Patent No. 5945511
;  GENERAL INFORMATION:
;    APPLICANT:  Lok, Si
;    APPLICANT:  Kho, Choon J.
;    APPLICANT:  Jelmberg, Anna C.
;    APPLICANT:  Adams, Robyn L.
;    APPLICANT:  Whitmore, Theodore E.
;    APPLICANT:  Farrah, Theresa M.
;    TITLE OF INVENTION:  CYTOKINE RECEPTOR
;    NUMBER OF SEQUENCES:  60
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  ZymoGenetics, Inc.
;      STREET:  1201 Eastlake Avenue East
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98102
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/943,087
;      FILING DATE:
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/803,305
;      FILING DATE:  20-FEB-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Lunn, Paul G
;      REGISTRATION NUMBER:  32,743
;      REFERENCE/DOCKET NUMBER:  96-24C1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-442-6627
;      TELEFAX:  206-442-6678
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  58:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  221 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  protein
;    FRAGMENT TYPE:  internal
US-08-943-087-58

  Query Match             17.0%;  Score 194.5;  DB 2;  Length 221;
  Best Local Similarity   26.8%;  Pred. No. 1.4e-15;
  Matches   56;  Conservative   44;  Mismatches   94;  Indels   15;  Gaps    8;

Qy      10 HVKFQSSNFENILTWDSGPEGTP--DTVYSIEYKTYGERDWVAKKGCQRITRKSCNLTVE 67
           ::  |  |  :|:|  |  :  |||        |:::|   ||:: |: |   |: | |   |:|: :
Db      13 NITFLSINMKNVLQW-TPPEGLQGVKVTYTVQYFIYGQKKWLNKSDCRNINRTYCDLSAD 71

Qy      68 TGNLTELYYARVTAVSAGGRSATKMTD--RFSSLQHTTLKPPDVTCISKVRSIQMIVHPT 125
           |  :     |||:|  |:    |   :|  |  ||      | : ||:|   :  :|| :::
Db      72 TSDYDHQYYAKVKAI--WGTKCSKWADSGRFYPFLDTQIGPPEVALTTDEKSISVVLTAP 129

Qy     126 PTPIRAGDGHRLTLEDIFHDLFYH---LELQVNRTYQMHLGGKQREYEFFGLTPDTEFLG 182
           |  |   :::: |: :| |:    |  : |||:   :             | |:|  :
Db     130 EKWKRNPDDLPVSMQQIYSNLKYNVSVLNTKSNRTWSQCV--TNHTLVLTWLEPNTLYCV 187

Qy     183 TIMICVPTWAKESAP--YMCRVKTLPDRT 209
           :  ||   : : |    |  :|| |::
Db     188 HVESFVPGPPRRAQPSEKQC-ARTLKDQS 215


RESULT 3
US-08-943-087-56
; Sequence 56, Application US/08943087
; Patent No. 5945511
;  GENERAL INFORMATION:
;    APPLICANT:  Lok, Si
;    APPLICANT:  Kho, Choon J.
;    APPLICANT:  Jelmberg, Anna C.
;    APPLICANT:  Adams, Robyn L.
;    APPLICANT:  Whitmore, Theodore E.
;    APPLICANT:  Farrah, Theresa M.
;    TITLE OF INVENTION:  CYTOKINE RECEPTOR
;    NUMBER OF SEQUENCES:  60
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  ZymoGenetics, Inc.
;      STREET:  1201 Eastlake Avenue East
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98102
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/943,087
;      FILING DATE:
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/803,305
;      FILING DATE:  20-FEB-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Lunn, Paul G
;      REGISTRATION NUMBER:  32,743
;      REFERENCE/DOCKET NUMBER:  96-24C1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  206-442-6627
;      TELEFAX:  206-442-6678
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  56:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  221 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  protein
;    FRAGMENT TYPE:  internal
US-08-943-087-56

  Query Match             16.9%;  Score 192.5;  DB 2;  Length 221;
  Best Local Similarity   25.6%;  Pred. No. 2.5e-15;
  Matches   55;  Conservative   44;  Mismatches   89;  Indels   27;  Gaps    8;

Qy      10 HVKFQSSNFENILTWDSGPEGTP--DTVYSIEYKTYGERDWVAKKGCQRITRKSCNLTVE 67
```

GenCore version 5.1.3

OM protein - protein search, using sw model

Run on: January 13, 2003, 15:28:46 ; Search time 29.223 Seconds
(without alignments)
962.115 Million cell updates/sec

Title: US-09-728-911-34
Perfect score: 1142
Sequence: 1 PEDPSDLLQHVKFQSSNFEN.....AKESAPYMCRVKTLPDRTWT 211

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1142	100.0	211	20	AAW97864	Human cytokine rec
2	1142	100.0	211	22	AAB62666	Human zcytor11 rec
3	1142	100.0	211	23	AAU76906	Human Z-cytor-II s
4	1142	100.0	484	23	AAU76916	Human zcytorII/IgG
5	1142	100.0	574	20	AAW97861	Human cytokine rec
6	1142	100.0	574	21	AAY97045	Human TANGO 241.
7	1142	100.0	574	22	AAE05047	Human ZCYTO18 rece
8	1142	100.0	574	22	AAB62665	Human zcytor11 rec
9	1142	100.0	574	22	AAB87607	Human PRO20233. H
10	1142	100.0	574	23	AAU76905	Human Z-cytor-II p
11	1142	100.0	574	23	AAU78083	Human interleukin
12	854	74.8	196	22	AAM24345	Human EST encoded
13	691	60.5	353	21	AAY97047	Partial murine TAN
14	263	23.0	210	22	AAB62663	Human zcytor16 ext
15	263	23.0	214	23	AAE17319	Human cytokine rec
16	263	23.0	231	22	AAE05048	Human ZCYTO18 solu
17	263	23.0	231	22	AAE02460	Human DNAX cytokin
18	263	23.0	231	22	AAB62657	Human cytokine rec
19	263	23.0	231	23	AAO17381	Human cytokine rec
20	263	23.0	231	23	AAU80000	Human IL-TIF/IL-22
21	263	23.0	231	23	ABG34086	Human Pro peptide
22	263	23.0	231	23	AAE17320	Human cytokine rec
23	237	20.8	262	22	AAU09186	Human PRO19598 pol
24	237	20.8	263	23	AAO17382	Human cytokine rec
25	237	20.8	263	23	AAU80324	Human IL-TIF/IL-22
26	237	20.8	263	23	AAE17321	Human cytokine rec
27	206.5	18.1	130	22	AAE02461	Human DNAX cytokin
28	203	17.8	249	22	AAE02458	Human DNAX cytokin
29	203	17.8	249	23	AAO17380	Human cytokine rec
30	191.5	16.8	217	22	AAB85280	IL-20RA-Ig gamma1
31	191.5	16.8	217	23	ABG67211	Interleukin-20 sub
32	191.5	16.8	221	22	AAB85269	Human IL-20 recept
33	191.5	16.8	221	23	ABG67200	Human Interleukin-
34	191.5	16.8	221	23	AAE23354	Human IL-20RA matu
35	191.5	16.8	542	22	AAU29222	Human PRO polypept
36	191.5	16.8	542	22	AAU12265	Human PRO4978 poly
37	191.5	16.8	547	22	AAB85279	Human IL-20RA-Ig g
38	191.5	16.8	547	23	ABG67210	Interleukin-20RB/I
39	191.5	16.8	547	23	AAE23362	Human IL-20RA EC d
40	191.5	16.8	553	19	AAW79159	Zcytor7 cytokine r
41	191.5	16.8	553	22	ABB11582	Human class II cyt
42	191.5	16.8	553	22	AAU04058	Human interleukin-
43	191.5	16.8	553	22	AAB85268	Human IL-20 recept
44	191.5	16.8	553	23	ABG67199	Human Interleukin-
45	191.5	16.8	553	23	AAE23353	Human interleukin-

ALIGNMENTS

RESULT 1
AAW97864
ID AAW97864 standard; Protein; 211 AA.
XX
AC AAW97864;
XX
DT 07-JUN-1999 (first entry)
XX
DE Human cytokine receptor 11 (Zcytor11) extracellular domain.
XX
KW Cytokine receptor 11; Zcytor11; human; pancreas; small intestine;
KW colon; thymus.
XX
OS Homo sapiens.
XX
PN WO9907848-A1.
XX
PD 18-FEB-1999.
XX
PF 30-JUL-1998; 98WO-US15847.
XX
PR 05-AUG-1997; 97US-0906713.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Adams RL, Farrah TM, Jelmberg AC, Lok S, Whitemore TE;
XX
DR WPI; 1999-167425/14.
XX
PT Novel human cytokine receptor Zcytor11 - useful for screening for
PT ligands to modulate or promote proliferation and/or differentiation
PT of e.g. pancreatic or colon tissue
XX

```
PS   Claim 20; Page 58-59; 62pp; English.
XX
CC   This polypeptide comprises the extracellular domain (residues
CC   18-228) of human cytokine receptor 11 (Zcytor11), a novel class II
CC   cytokine receptor that appears to be a receptor for a helical
CC   cytokine of the interferon/interleukin-10 class.  Zcytor11 (see
CC   also AAW97861) is a cell surface receptor that is expressed in
CC   pancreas, small intestine, colon and thymus.  Novel Zcytor11
CC   polypeptides, including the extracellular domain, can be used to
CC   detect ligands that promote the proliferation and/or differentiation
CC   of these organs.  The invention provides claimed expression vectors
CC   and transformed or transfected cells, as well as an antibody that
CC   specifically binds to the extracellular domain of Zcytor11, and an
CC   anti-idiotyptic antibody.  The vectors include a promoter, a
CC   terminator and DNA encoding the extracellular domain, signal
CC   sequence, transmembrane domain (see AAW97865) or intracellular domain
CC   (see AAW97866) of Zcytor11.
XX
SQ   Sequence   211 AA;

  Query Match             100.0%;  Score 1142;  DB 20;  Length 211;
  Best Local Similarity   100.0%;  Pred. No. 3.3e-121;
  Matches  211;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60

Qy      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120

Qy     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180

Qy     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
          |||||||||||||||||||||||||||||||
Db     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211


RESULT 2
AAB62666
ID   AAB62666 standard; Protein; 211 AA.
XX
AC   AAB62666;
XX
DT   23-JUL-2001  (first entry)
XX
DE   Human zcytor11 receptor fragment.
XX
KW   Cytokine receptor; zcytor16; IL-TIF; antiinflammatory; cytostatic;
KW   antirheumatic; antiarthritic; antiasthmatic; antiatherosclerotic;
KW   immunosuppressive; chromosome 6q24.1-25.2; human; zcytor11.
XX
OS   Homo sapiens.
XX
PN   WO200140467-A1.
XX
PD   07-JUN-2001.
XX
PF   01-DEC-2000; 2000WO-US32703.
XX
PR   03-DEC-1999;   99US-0169049.
PR   13-SEP-2000; 2000US-0232219.
PR   31-OCT-2000; 2000US-0244610.
XX
PA   (ZYMO ) ZYMOGENETICS INC.
XX
PI   Presnell SR,  Xu W,  Kindsvogel W,  Chen Z;
XX
DR   WPI; 2001-356158/37.
XX
PT   New soluble cytokine receptor polypeptides and polynucleotides, useful
PT   for diagnosing and treating cancer and inflammatory conditions -
XX
PS   Claim 46; Page 206-207; 210pp; English.
XX
CC   The invention relates to a human cytokine receptor polypeptide,
CC   designated zcytor16. The zcytor16 polypeptide can be expressed by
CC   standard recombinant methodology and can bind to IL-TIF (undefined). The
CC   zcytor16 protein is useful for: inhibiting IL-TIF induced proliferation
CC   or differentiation of hematopoietic cell(s) (progenitors); reducing
CC   IL-TIF induced or IL-9 induced inflammation; and suppressing an
CC   inflammatory response in a mammal with inflammation. Heteromeric/
CC   multimeric receptor polypeptides such as soluble zcytor 16/CRF2-4 can be
CC   used to reduce progression and symptoms of cancer. Zcytor16 polypeptides
CC   can also be used to detect IL-TIF levels which is indicative of
CC   pathological conditions including inflammatory states (e.g. rheumatoid
CC   arthritis) and cancer. Antibodies that bind zcytor16 polypeptides and the
CC   polypeptides themselves are useful for the treatment of inflammation,
CC   inflammatory diseases (e.g. infection, asthma, inflammatory bowel
CC   disease, rheumatoid arthritis and atherosclerosis) and autoimmune
CC   diseases. The antibodies and zcytor16 polynucleotides are also useful
CC   for detecting cancer. The present sequence represents the human zcytor11
CC   receptor protein fragment which forms a receptor complex with zcytor16.
XX
SQ   Sequence   211 AA;

  Query Match             100.0%;  Score 1142;  DB 22;  Length 211;
  Best Local Similarity   100.0%;  Pred. No. 3.3e-121;
  Matches  211;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60

Qy      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120

Qy     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180

Qy     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
          |||||||||||||||||||||||||||||||
Db     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211


RESULT 3
AAU76906
ID   AAU76906 standard; Protein; 211 AA.
XX
AC   AAU76906;
XX
DT   05-JUN-2002  (first entry)
XX
DE   Human Z-cytor-II soluble extracellular domain protein.
XX
KW   Z-Cytor II; human; cytokine receptor; atopy; psoriasis;
KW   interleukin-T-cell inducible factor; IL-TIF; allergy; asthma;
KW   receptor-modulated apoptosis; Th1; immune response; pancreatitis;
KW   type I diabetes; IDDM; pancreatic cancer; Graves disease; SLE;
KW   inflammatory bowel disease; IBD; Crohn's disease; colon cancer;
KW   intestinal cancer; diverticulosis; autoimmune disease; sepsis;
KW   multiple sclerosis; MS; systemic lupus erythematosus;
KW   myasthaenia gravis; rheumatoid arthritis; kidney dysfunction.
XX
OS   Homo sapiens.
XX
PN   WO200212345-A2.
XX
PD   14-FEB-2002.
XX
PF   08-AUG-2001; 2001WO-US24838.
```

XX
PR 08-AUG-2000; 2000US-223827P.
PR 01-DEC-2000; 2000US-250876P.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Kindsvogel WR, Topouzis S;
XX
DR WPI; 2002-217182/27.
DR N-PSDB; AEK10501.
XX
PT New soluble cytokine receptor which binds interleukin-T-cell inducible
PT factor and antagonizes its activity in inflammatory and immune diseases
PT such as cancer, diabetes, asthma, sepsis, psoriasis and autoimmune
PT diseases -
XX
PS Claim 31; Page 94-95; 117pp; English.
XX
CC This invention relates to the protein and cDNA sequences of a novel
CC soluble cytokine receptor polypeptide designated zcytorII, which binds
CC interleukin-T-cell inducible factor (IL-TIF) or antagonises IL-TIF
CC activity. The protein of the invention is useful for reducing IL-TIF-
CC or IL-9 induced inflammation, and inhibiting IL-TIF-induced
CC proliferation. The protein is also useful for suppressing an immune
CC response in a mammal exposed to an antigen or pathogen. Soluble zcytorII
CC receptor or heterodimeric polypeptide is useful for enhancing the in
CC vivo killing of target tissues by directly stimulating a zcytorII
CC receptor-modulated apoptotic pathway. IL-TIF is involved in promoting
CC Th1-type immune responses and antagonists of IL-TIF have beneficial use
CC against diseases involving such immune responses. Soluble zcytorII
CC heterodimers are useful as antagonists in inflammatory and immune
CC diseases or conditions such as pancreatitis, type I diabetes (IDDM),
CC pancreatic cancer, Graves disease, inflammatory bowel disease (IBD),
CC Crohn's disease, colon and intestinal cancer, diverticulosis, autoimmune
CC disease (e.g. IDDM, multiple sclerosis (MS), systemic lupus
CC erythematosus (SLE), myasthaenia gravis, rheumatoid arthritis and IBD),
CC sepsis, asthma,allergy and other atopic diseases, psoriasis and kidney
CC dysfunction. Soluble zcytorII receptor or heterodimeric receptor
CC polypeptides are useful in vivo or in diagnostic applications to detect
CC IL-TIF expressing cancers in vivo or in tissue samples and to prepare
CC antibodies. ZcytoRII serves as a target for MAb therapy of cancer where
CC an antagonising MAb inhibits cancer growth and targets immune-mediated
CC killing. The present sequence represents the soluble extracellular
CC domain of the ZcytoRII protein of the invention
XX
SQ Sequence 211 AA;

Query Match 100.0%; Score 1142; DB 23; Length 211;
Best Local Similarity 100.0%; Pred. No. 3.3e-121;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60

Qy      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120

Qy     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180

Qy     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
          |||||||||||||||||||||||||||||||
Db     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
```

RESULT 4
AAU76916
ID AAU76916 standard; Protein; 484 AA.
XX
AC AAU76916;

XX
DT 05-JUN-2002 (first entry)
XX
DE Human zcytorII/IgGgammaI fusion protein with Glu-Glu tag.
XX
KW Z-Cytor II; human; cytokine receptor; atopy; psoriasis;
KW interleukin-T-cell inducible factor; IL-TIF; allergy; asthma;
KW receptor-modulated apoptosis; Th1; immune response; pancreatitis;
KW type I diabetes; IDDM; pancreatic cancer; Graves disease; SLE;
KW inflammatory bowel disease; IBD; Crohn's disease; colon cancer;
KW intestinal cancer; diverticulosis; autoimmune disease; sepsis;
KW multiple sclerosis; MS; systemic lupus erythematosus;
KW myasthaenia gravis; rheumatoid arthritis; kidney dysfunction.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200212345-A2.
XX
PD 14-FEB-2002.
XX
PF 08-AUG-2001; 2001WO-US24838.
XX
PR 08-AUG-2000; 2000US-223827P.
PR 01-DEC-2000; 2000US-250876P.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Kindsvogel WR, Topouzis S;
XX
DR WPI; 2002-217182/27.
DR N-PSDB; ABK10522.
XX
PT New soluble cytokine receptor which binds interleukin-T-cell inducible
PT factor and antagonizes its activity in inflammatory and immune diseases
PT such as cancer, diabetes, asthma, sepsis, psoriasis and autoimmune
PT diseases -
XX
PS Example 7; Page 113-114; 117pp; English.
XX
CC This invention relates to the protein and cDNA sequences of a novel
CC soluble cytokine receptor polypeptide designated zcytorII, which binds
CC interleukin-T-cell inducible factor (IL-TIF) or antagonises IL-TIF
CC activity. The protein of the invention is useful for reducing IL-TIF-
CC or IL-9 induced inflammation, and inhibiting IL-TIF-induced
CC proliferation. The protein is also useful for suppressing an immune
CC response in a mammal exposed to an antigen or pathogen. Soluble zcytorII
CC receptor or heterodimeric polypeptide is useful for enhancing the in
CC vivo killing of target tissues by directly stimulating a zcytorII
CC receptor-modulated apoptotic pathway. IL-TIF is involved in promoting
CC Th1-type immune responses and antagonists of IL-TIF have beneficial use
CC against diseases involving such immune responses. Soluble zcytorII
CC heterodimers are useful as antagonists in inflammatory and immune
CC diseases or conditions such as pancreatitis, type I diabetes (IDDM),
CC pancreatic cancer, Graves disease, inflammatory bowel disease (IBD),
CC Crohn's disease, colon and intestinal cancer, diverticulosis, autoimmune
CC disease (e.g. IDDM, multiple sclerosis (MS), systemic lupus
CC erythematosus (SLE), myasthaenia gravis, rheumatoid arthritis and IBD),
CC sepsis, asthma,allergy and other atopic diseases, psoriasis and kidney
CC dysfunction. Soluble zcytorII receptor or heterodimeric receptor
CC polypeptides are useful in vivo or in diagnostic applications to detect
CC IL-TIF expressing cancers in vivo or in tissue samples and to prepare
CC antibodies. ZcytoRII serves as a target for MAb therapy of cancer where
CC an antagonising MAb inhibits cancer growth and targets immune-mediated
CC killing. The present sequence represents the ZcytorII/IgGII fusion
CC protein of the invention
XX
SQ Sequence 484 AA;

Query Match 100.0%; Score 1142; DB 23; Length 484;
Best Local Similarity 100.0%; Pred. No. 1.2e-120;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 77

Qy      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      78 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

Qy     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 197

Qy     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
           |||||||||||||||||||||||||||||||
Db     198 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 228
```

RESULT 5
AAW97861
ID AAW97861 standard; Protein; 574 AA.
XX
AC AAW97861;
XX
DT 07-JUN-1999 (first entry)
XX
DE Human cytokine receptor 11 (Zcytor11).
XX
KW Cytokine receptor 11; Zcytor11; human; pancreas; small intestine;
KW colon; thymus.
XX
OS Homo sapiens.
XX

FH	Key	Location/Qualifiers
FT	Peptide	1..17
FT		/note= "signal peptide"
FT	Protein	18..574
FT		/note= "mature protein"
FT	Domain	18..228
FT		/note= "extracellular domain, this region is
FT		specifically claimed in Claim 20"
FT	Domain	229..251
FT		/note= "transmembrane domain"
FT	Domain	252..574
FT		/note= "intracellular domain"
FT	Protein	1..228
FT		/note= "this polypeptide is specifically claimed
FT		in Claim 27"
FT	Protein	1..251
FT		/note= "this polypeptide is specifically claimed
FT		in Claim 27"
FT	Protein	1..574
FT		/note= "this polypeptide is specifically claimed
FT		in Claim 27"
FT	Protein	2..228
FT		/note= "this polypeptide is specifically claimed
FT		in Claim 27"
FT	Protein	2..551
FT		/note= "this polypeptide is specifically claimed
FT		in Claim 27"
FT	Protein	2..574
FT		/note= "this polypeptide is specifically claimed
FT		in Claim 27"

XX
PN WO9907848-A1.
XX
PD 18-FEB-1999.
XX
PF 30-JUL-1998; 98WO-US15847.
XX
PR 05-AUG-1997; 97US-0906713.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Adams RL, Farrah TM, Jelmberg AC, Lok S, Whitemore TE;
XX
DR WPI; 1999-167425/14.
DR N-PSDB; AAX24379.
XX
PT Novel human cytokine receptor Zcytor11 - useful for screening for
PT ligands to modulate or promote proliferation and/or differentiation
PT of e.g. pancreatic or colon tissue
XX
PS Claim 27; Page 54-56; 62pp; English.
XX
CC This is the amino acid sequence of human cytokine receptor 11
CC (Zcytor11), a novel class II cytokine receptor that appears to be a
CC receptor for a helical cytokine of the interferon/interleukin-10
CC class. The sequence was deduced from the nucleotide sequence (see
CC AAX24379) of a cDNA clone obtained from pancreatic islet cDNA
CC library. Zcytor11 is a cell surface receptor that is expressed in
CC pancreas, small intestine, colon and thymus. Novel Zcytor11
CC polypeptides, especially an extracellular domain (see AAW97864) of
CC Zcytor11, can be used to detect ligands that promote the
CC proliferation and/or differentiation of these organs. The
CC invention provides claimed expression vectors and transformed or
CC transfected cells, as well as an antibody that specifically binds
CC to the extracellular domain of Zcytor11, and an anti-idiotyptic
CC antibody. The vectors include a promoter, a terminator and DNA
CC encoding the extracellular domain, signal sequence, transmembrane
CC domain or intracellular domain of Zcytor11.
XX
SQ Sequence 574 AA;

Query Match 100.0%; Score 1142; DB 20; Length 574;
Best Local Similarity 100.0%; Pred. No. 1.5e-120;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 77

Qy      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      78 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

Qy     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 197

Qy     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
           |||||||||||||||||||||||||||||||
Db     198 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 228
```

RESULT 6
AAY97045
ID AAY97045 standard; Protein; 574 AA.
XX
AC AAY97045;
XX
DT 31-OCT-2000 (first entry)
XX
DE Human TANGO 241.
XX
KW TANGO 241; transmembrane; class II; cytokine receptor; chromosome 1p36;
KW cytostatic; cerebroprotective; immunomodulatory; anti-inflammatory;
KW virucide; antibacterial; vasotropic.
XX
OS Homo sapiens.
XX

FH	Key	Location/Qualifiers
FT	Active-site	1..14
FT		/label= Signal_peptide
FT	Protein	1..222
FT		/label= Mature_protein
FT	Domain	15..226

```
FT                   /label= Extracellular_domain
FT   Domain          38..105
FT                   /label= Fibronectin_III_domain
FT   Modified-site   80
FT                   /note= "N-linked glycosylation site"
FT   Modified-site   87
FT                   /note= "N-linked glycosylation site"
FT   Modified-site   172
FT                   /note= "N-linked glycosylation site"
FT   Domain          227..251
FT                   /label= Transmembrane_domain
FT   Domain          252..574
FT                   /label= Cytoplasmic_domain
FT   Misc-difference 372..381
FT                   /label= Box-3-like_element
FT                   /note= "Involved in STAT binding"
XX
PN   WO200039161-A1.
XX
PD   06-JUL-2000.
XX
PF   30-DEC-1999;   99WO-US31328.
XX
PR   31-DEC-1998;   98US-0224669.
XX
PA   (MILL-) MILLENNIUM PHARM INC.
XX
PI   Busfield SJ;
XX
DR   WPI; 2000-452372/39.
DR   N-PSDB; AAA51869, AAA51870.
XX
PT   New nucleic acid molecules encoding polypeptides designated TANGO 241
PT   and TANGO 242 used for treating e.g. brain and pancreatic disorders
XX
PS   Claim 8; Fig 1A-B; 127pp; English.
XX
CC   Novel transmembrane proteins, designated TANGO 241 and TANGO 242, are
CC   members of the class II cytokine receptor superfamily. The TANGO 241 and
CC   242 genes have been localized to human chromosomes 1p36 and 3q21,
CC   respectively. The proteins, cDNA and their modulators can be used for the
CC   treatment of viral and bacterial infection, inflammatory and autoimmune
CC   disorders, vascular injury and inhibition of angiogenesis. In particular,
CC   TANGO 241 can be used to treat pancreatic disorders and TANGO 242 can be
CC   used to treat brain disorders.
XX
SQ   Sequence   574 AA;

  Query Match           100.0%;  Score 1142;  DB 21;  Length 574;
  Best Local Similarity 100.0%;  Pred. No. 1.5e-120;
  Matches  211;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 77

Qy      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      78 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

Qy     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 197

Qy     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
          |||||||||||||||||||||||||||||||
Db     198 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 228


RESULT 7
AAE05047
ID   AAE05047 standard; Protein; 574 AA.
XX
AC   AAE05047;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human ZCYTO18 receptor protein, zcytor11.
XX
KW   Human; cytostatic; cytokine; ZCYTO18 protein; genetic abnormality;
KW   cancer; inflammation; gene therapy; zcytor11.
XX
OS   Homo sapiens.
XX
PN   WO200146422-A1.
XX
PD   28-JUN-2001.
XX
PF   22-DEC-2000; 2000WO-US35308.
XX
PR   23-DEC-1999;   99US-0471767.
PR   01-DEC-2000; 2000US-0250841.
XX
PA   (ZYMO ) ZYMOGENETICS INC.
XX
PI   Presnell SR,  Kindsvogel W;
XX
DR   WPI; 2001-408648/43.
DR   N-PSDB; AAD09732.
XX
PT   Novel human cytokine polypeptide, ZCYTO18, useful for treating cancer -
XX
PS   Claim 1; Page 151-153; 167pp; English.
XX
CC   The patent discloses novel human cytokine, ZCYTO18 protein and its
CC   corresponding DNA. ZCYTO18 protein induces proliferation of cells
CC   expressing zcytor11, a receptor for ZCYTO18 or induces cytotoxicity
CC   in K5626 cells. ZCYTO18 DNA is useful for detecting a genetic
CC   abnormality in a patient. ZCYTO18 DNA and its antibodies are useful
CC   for detecting cancer and inflammation. ZCYTO18 protein is useful for
CC   killing cancer cells. It is useful for increasing platelets in a
CC   patient or injured tissue. It is also used in gene therapy.
CC   The present sequence is human zcytor11, which is a receptor for
CC   ZCYTO18 protein.
XX
SQ   Sequence   574 AA;

  Query Match           100.0%;  Score 1142;  DB 22;  Length 574;
  Best Local Similarity 100.0%;  Pred. No. 1.5e-120;
  Matches  211;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 77

Qy      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      78 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

Qy     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 197

Qy     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
          |||||||||||||||||||||||||||||||
Db     198 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 228


RESULT 8
AAB62665
ID   AAB62665 standard; Protein; 574 AA.
XX
AC   AAB62665;
XX
DT   23-JUL-2001  (first entry)
XX
```

DE Human zcytor11 receptor.
XX
KW Cytokine receptor; zcytor16; IL-TIF; antiinflammatory; cytostatic;
KW antirheumatic; antiarthritic; antiasthmatic; antiatherosclerotic;
KW immunosuppressive; chromosome 6q24.1-25.2; human; zcytor11.
XX
OS Homo sapiens.
XX
PN WO200140467-A1.
XX
PD 07-JUN-2001.
XX
PF 01-DEC-2000; 2000WO-US32703.
XX
PR 03-DEC-1999; 99US-0169049.
PR 13-SEP-2000; 2000US-0232219.
PR 31-OCT-2000; 2000US-0244610.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Presnell SR, Xu W, Kindsvogel W, Chen Z;
XX
DR WPI; 2001-356158/37.
DR N-PSDB; AAF83750.
XX
PT New soluble cytokine receptor polypeptides and polynucleotides, useful
PT for diagnosing and treating cancer and inflammatory conditions -
XX
PS Example 13; Page 202-204; 210pp; English.
XX
CC The invention relates to a human cytokine receptor polypeptide,
CC designated zcytor16. The zcytor16 polypeptide can be expressed by
CC standard recombinant methodology and can bind to IL-TIF (undefined). The
CC zcytor16 protein is useful for: inhibiting IL-TIF induced proliferation
CC or differentiation of hematopoietic cell(s) (progenitors); reducing
CC IL-TIF induced or IL-9 induced inflammation; and suppressing an
CC inflammatory response in a mammal with inflammation. Heteromeric/
CC multimeric receptor polypeptides such as soluble zcytor 16/CRF2-4 can be
CC used to reduce progression and symptoms of cancer. Zcytor16 polypeptides
CC can also be used to detect IL-TIF levels which is indicative of
CC pathological conditions including inflammatory states (e.g. rheumatoid
CC arthritis) and cancer. Antibodies that bind zcytor16 polypeptides and the
CC polypeptides themselves are useful for the treatment of inflammation,
CC inflammatory diseases (e.g. infection, asthma, inflammatory bowel
CC disease, rheumatoid arthritis and atherosclerosis) and autoimmune
CC diseases. The antibodies and zcytor16 polynucleotides are also useful
CC for detecting cancer. The present sequence represents the human zcytor11
CC receptor protein.
XX
SQ Sequence 574 AA;

Query Match 100.0%; Score 1142; DB 22; Length 574;
Best Local Similarity 100.0%; Pred. No. 1.5e-120;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 77

Qy     61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     78 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

Qy    121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 197

Qy    181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
          |||||||||||||||||||||||||||||||
Db    198 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 228
```

RESULT 9

AAB87607
ID AAB87607 standard; Protein; 574 AA.
XX
AC AAB87607;
XX
DT 15-MAY-2001 (first entry)
XX
DE Human PRO20233.
XX
KW Human; PRO protein; mapping.
XX
OS Homo sapiens.
XX
PN WO200116318-A2.
XX
PD 08-MAR-2001.
XX
PF 24-AUG-2000; 2000WO-US23328.
XX
PR 01-SEP-1999; 99WO-US20111.
PR 15-SEP-1999; 99WO-US21090.
PR 07-DEC-1999; 99US-0169495.
PR 09-DEC-1999; 99US-0170262.
PR 11-JAN-2000; 2000US-0175481.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 01-MAR-2000; 2000WO-US05601.
PR 03-MAR-2000; 2000US-0187202.
PR 25-APR-2000; 2000US-0199397.
PR 22-MAY-2000; 2000WO-US14042.
PR 05-JUN-2000; 2000US-0209832.
XX
PA (GETH) GENENTECH INC.
XX
PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi CJ, Gurney AL, Watanabe CK, Wood WI;
XX
DR WPI; 2001-183260/18.
DR N-PSDB; AAF92139.
XX
PT Eighty four nucleic acids encoding PRO polypeptides, useful in
PT molecular biology, including use as hybridization probes, and in
PT chromosome and gene mapping. -
XX
PS Claim 12; Fig 164; 278pp; English.
XX
CC The present sequence is a human PRO polypeptide (secreted and
CC transmembrane). The PRO protein, and PRO agonists, PRO antagonists or
CC anti-PRO antibodies are useful for preparation of a medicament useful in
CC the treatment of a condition which is responsive to the PRO protein,
CC agonists, antagonists or anti-PRO antibodies. The PRO protein may also be
CC employed as molecular weight markers for protein electrophoresis. The PRO
CC coding sequence has applications in molecular biology, including use as
CC hybridisation probes, and in chromosome and gene mapping.
XX
SQ Sequence 574 AA;

Query Match 100.0%; Score 1142; DB 22; Length 574;
Best Local Similarity 100.0%; Pred. No. 1.5e-120;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 77

Qy     61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     78 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

Qy    121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 197
```

```
Qy     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
           |||||||||||||||||||||||||||||||
Db     198 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 228
```

RESULT 10
AAU76905
ID AAU76905 standard; Protein; 574 AA.
XX
AC AAU76905;
XX
DT 05-JUN-2002 (first entry)
XX
DE Human Z-cytor-II protein.
XX
KW Z-Cytor II; human; cytokine receptor; atopy; psoriasis;
KW interleukin-T-cell inducible factor; IL-TIF; allergy; asthma;
KW receptor-modulated apoptosis; Th1; immune response; pancreatitis;
KW type I diabetes; IDDM; pancreatic cancer; Graves disease; SLE;
KW inflammatory bowel disease; IBD; Crohn's disease; colon cancer;
KW intestinal cancer; diverticulosis; autoimmune disease; sepsis;
KW multiple sclerosis; MS; systemic lupus erythematosus;
KW myasthaenia gravis; rheumatoid arthritis; kidney dysfunction.
XX
OS Homo sapiens.
XX
FH Key   Location/Qualifiers
FT Region   17..228
FT   /note= " Soluble extracellular domain"
XX
PN WO200212345-A2.
XX
PD 14-FEB-2002.
XX
PF 08-AUG-2001; 2001WO-US24838.
XX
PR 08-AUG-2000; 2000US-223827P.
PR 01-DEC-2000; 2000US-250876P.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Kindsvogel WR, Topouzis S;
XX
DR WPI; 2002-217182/27.
DR N-PSDB; ABK10501.
XX
PT New soluble cytokine receptor which binds interleukin-T-cell inducible
PT factor and antagonizes its activity in inflammatory and immune diseases
PT such as cancer, diabetes, asthma, sepsis, psoriasis and autoimmune
PT diseases -
XX
PS Example 8; Page 92-94; 117pp; English.
XX
CC This invention relates to the protein and cDNA sequences of a novel
CC soluble cytokine receptor polypeptide designated zcytorII, which binds
CC interleukin-T-cell inducible factor (IL-TIF) or antagonises IL-TIF
CC activity. The protein of the invention is useful for reducing IL-TIF-
CC or IL-9 induced inflammation, and inhibiting IL-TIF-induced
CC proliferation. The protein is also useful for suppressing an immune
CC response in a mammal exposed to an antigen or pathogen. Soluble zcytorII
CC receptor or heterodimeric polypeptide is useful for enhancing the in
CC vivo killing of target tissues by directly stimulating a zcytorII
CC receptor-modulated apoptotic pathway. IL-TIF is involved in promoting
CC Th1-type immune responses and antagonists of IL-TIF have beneficial use
CC against diseases involving such immune responses. Soluble zcytorII
CC heterodimers are useful as antagonists in inflammatory and immune
CC diseases or conditions such as pancreatitis, type I diabetes (IDDM),
CC pancreatic cancer, Graves disease, inflammatory bowel disease (IBD),
CC Crohn's disease, colon and intestinal cancer, diverticulosis, autoimmune
CC disease (e.g. IDDM, multiple sclerosis (MS), systemic lupus
CC erythematosus (SLE), myasthaenia gravis, rheumatoid arthritis and IBD),
CC sepsis, asthma,allergy and other atopic diseases, psoriasis and kidney
CC dysfunction. Soluble zcytor1II receptor or heterodimeric receptor
CC polypeptides are useful in vivo or in diagnostic applications to detect
CC IL-TIF expressing cancers in vivo or in tissue samples and to prepare
CC antibodies. ZcytoRII serves as a target for MAb therapy of cancer where
CC an antagonising MAb inhibits cancer growth and targets immune-mediated
CC killing. The present sequence represents the ZcytorII protein of the
CC invention
XX
SQ Sequence 574 AA;

```
  Query Match             100.0%;  Score 1142;  DB 23;  Length 574;
  Best Local Similarity   100.0%;  Pred. No. 1.5e-120;
  Matches  211;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 77

Qy      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      78 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

Qy     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 197

Qy     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
           |||||||||||||||||||||||||||||||
Db     198 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 228
```

RESULT 11
AAU78083
ID AAU78083 standard; Protein; 574 AA.
XX
AC AAU78083;
XX
DT 05-JUN-2002 (first entry)
XX
DE Human interleukin 22 receptor (IL-22R) protein sequence.
XX
KW Interleukin 22; IL-22; cytostatic; antiinflammatory; IL-22 antagonist;
KW immunotherapy; PAP1; pancreatitis associated protein; receptor;
KW IL-22R; IL-10Rbeta; bioactive molecule linkage; cell death; pancreatitis;
KW pancreatic disorder; pancreatic carcinoma; acinar cell carcinoma; human;
KW mixed cell population pancreatic carcinoma.
XX
OS Homo sapiens.
XX
PN WO200216611-A2.
XX
PD 28-FEB-2002.
XX
PF 30-MAY-2001; 2001WO-US17443.
XX
PR 24-AUG-2000; 2000WO-US23328.
XX
PA (GETH) GENENTECH INC.
XX
PI Aggarwal S, Foster JS, Goddard A, Gurney AL, Maruoka EM, Wood WI;
PI Xie M;
XX
DR WPI; 2002-280940/32.
XX
PT Novel isolated interleukin 22 polypeptide useful for identifying IL-22
PT agonists and antagonists that are used for treating acute pancreatitis,
PT chronic pancreatitis, pancreatic carcinoma -
XX
PS Example 2; Fig 11; 94pp; English.
XX
CC The present invention relates to a new polypeptide having at least 80%
CC identity to a 101 amino acid interleukin (IL)-22 sequence. The invention
CC is useful for detecting IL-22R (IL-22 receptor) or IL-10Rbeta polypeptide

CC in a sample which involves contacting sample with an IL-22 polypeptide
CC and determining the formation of an IL-22R/IL-22 polypeptide conjugate or
CC an IL-10Rbeta/IL-22 polypeptide conjugate. Preferably, the IL-22
CC polypeptide is labelled with a detectable label or is attached to a solid
CC support. The polypeptide is also useful for linking a bioactive molecule,
CC e.g. toxin, radiolabel or antibody that causes the death of the cell, to
CC a cell expressing IL-22R polypeptide or IL-10Rbeta polypeptide which
CC involves contacting the cell with IL-22 polypeptide that is bound to the
CC bioactive molecule and allowing binding of the IL-22 polypeptide with
CC IL-22R or IL-10Rbeta polypeptide thus linking the bioactive molecules to
CC the cell. The molecules of the invention can also be used for modulating
CC biological activity of cell expressing IL-22R or IL-10Rbeta polypeptide,
CC whereby the cell is killed and the antibody of the invention is useful
CC for inhibiting IL-22 induced expression of PAP1 (pancreatitis associated
CC protein) by pancreatic cells. The antibody is also useful for treating a
CC pancreatic disorder such as acute or chronic pancreatitis, pancreatic
CC carcinoma including acinar cell carcinoma or mixed cell population
CC pancreatic carcinoma and for reducing the activated or inflamed condition
CC of the pancreas in a mammal. The present amino acid sequence represents
CC the human interleukin 22 receptor (IL-22R) protein of the invention.
CC This sequence forms a receptor/ligand interaction with IL-22.
XX
SQ Sequence 574 AA;

Query Match 100.0%; Score 1142; DB 23; Length 574;
Best Local Similarity 100.0%; Pred. No. 1.5e-120;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 77

Qy      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      78 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

Qy     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 197

Qy     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
          |||||||||||||||||||||||||||||||
Db     198 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 228
```

RESULT 12
AAM24345
ID AAM24345 standard; Protein; 196 AA.
XX
AC AAM24345;
XX
DT 12-OCT-2001 (first entry)
XX
DE Human EST encoded protein SEQ ID NO: 1870.
XX
KW Human; sheep; pig; cow; fruit fly; yeast; hamster; macaque; horse;
KW tomato; monkey; dog; sea urchin; expressed sequence tag; EST;
KW diagnostics; forensic test; gene mapping; genetic disorder;
KW biodiversity; gene therapy; nutrition.
XX
OS Homo sapiens.
XX
PN WO200154477-A2.
XX
PD 02-AUG-2001.
XX
PF 25-JAN-2001; 2001WO-US02687.
XX
PR 25-JAN-2000; 2000US-0491404.
PR 17-JUL-2000; 2000US-0617746.
PR 03-AUG-2000; 2000US-0631451.
PR 15-SEP-2000; 2000US-0663870.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Zhou P, Qian XB, Wang Z, Chen R, Asundi V;
PI Cao Y, Drmanac RA, Zhang J, Werhman T;
XX
DR WPI; 2001-476164/51.
DR N-PSDB; AAH99004.
XX
PT Isolated polypeptide for treatment of diseases, diagnostics, raising
PT antibodies and research use -
XX
PS Claim 20; Page 1210; 1275pp; English.
XX
CC The present invention provides the protein and coding sequences of novel
CC proteins from a variety of organisms, including human, dog, cat, horse,
CC cow, pig, hamster, monkey, macaque, yeast, bacteria, fruit fly, sea
CC urchin and tomato. These were derived from expressed sequence tags (ESTs)
CC from the organism of interest. They can be used in diagnostics,
CC forensics, gene mapping, identification of mutations, to assess
CC biodiversity and for nutritional purposes. The present sequence is a
CC protein of the invention.
XX
SQ Sequence 196 AA;

Query Match 74.8%; Score 854; DB 22; Length 196;
Best Local Similarity 100.0%; Pred. No. 1.6e-88;
Matches 160; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 77

Qy      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      78 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

Qy     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQM 160
          |||||||||||||||||||||||||||||||||||||||||
Db     138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQM 177
```

RESULT 13
AAY97047
ID AAY97047 standard; Protein; 353 AA.
XX
AC AAY97047;
XX
DT 31-OCT-2000 (first entry)
XX
DE Partial murine TANGO 241.
XX
KW TANGO 241; transmembrane; class II; cytokine receptor; cytostatic;
KW cerebroprotective; immunomodulatory; anti-inflammatory; virucide;
KW antibacterial; vasotropic.
XX
OS Mus sp.
XX
PN WO200039161-A1.
XX
PD 06-JUL-2000.
XX
PF 30-DEC-1999; 99WO-US31328.
XX
PR 31-DEC-1998; 98US-0224669.
XX
PA (MILL-) MILLENNIUM PHARM INC.
XX
PI Busfield SJ;
XX
DR WPI; 2000-452372/39.
DR N-PSDB; AAA51873, AAA51874.
XX
PT New nucleic acid molecules encoding polypeptides designated TANGO 241

PT and TANGO 242 used for treating e.g. brain and pancreatic disorders
XX
PS Disclosure; Fig 7A-B; 127pp; English.
XX
CC Novel transmembrane proteins, designated TANGO 241 and TANGO 242, are
CC members of the class II cytokine receptor superfamily. The TANGO 241 and
CC 242 genes have been localized to human chromosomes 1p36 and 3q21,
CC respectively. The proteins, cDNA and their modulators can be used for the
CC treatment of viral and bacterial infection, inflammatory and autoimmune
CC disorders, vascular injury and inhibition of angiogenesis. In particular,
CC TANGO 241 can be used to treat pancreatic disorders and TANGO 242 can be
CC used to treat brain disorders.
XX
SQ Sequence 353 AA;

Query Match 60.5%; Score 691; DB 21; Length 353;
Best Local Similarity 78.5%; Pred. No. 1.3e-69;
Matches 128; Conservative 13; Mismatches 22; Indels 0; Gaps 0;

Qy 48 WVAKKGCQRITRKSCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPP 107
Db 1 WLAKAGCQRITQKFCNLTMETRNHTEFYYAKVTAVSAGGPPVTKMTDRFSSLQHTTIKPP 60

Qy 108 DVTCISKVRSIQMIVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQR 167
Db 61 DVTCIPKVRSIQMLVHPTLTPVLSEDGHQLTLEEIFHDLFYRLELHVNHTYQMHLEGKQR 120

Qy 168 EYEFFGLTPDTEFLGTIMICVPTWAKESAPYMCRVKTLPDRTW 210
Db 121 EYEFLGLTPDTEFLGSITILTPILSKESAPYVCRVKTLPDRTW 163

RESULT 14
AAB62663
ID AAB62663 standard; Protein; 210 AA.
XX
AC AAB62663;
XX
DT 23-JUL-2001 (first entry)
XX
DE Human zcytor16 extracellular domain fragment (residues 22-231).
XX
KW Cytokine receptor; zcytor16; IL-TIF; antiinflammatory; cytostatic;
KW antirheumatic; antiarthritic; antiasthmatic; antiatherosclerotic;
KW immunosuppressive; chromosome 6q24.1-25.2; human.
XX
OS Homo sapiens.
XX
PN WO200140467-A1.
XX
PD 07-JUN-2001.
XX
PF 01-DEC-2000; 2000WO-US32703.
XX
PR 03-DEC-1999; 99US-0169049.
PR 13-SEP-2000; 2000US-0232219.
PR 31-OCT-2000; 2000US-0244610.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Presnell SR, Xu W, Kindsvogel W, Chen Z;
XX
DR WPI; 2001-356158/37.
XX
PT New soluble cytokine receptor polypeptides and polynucleotides, useful
PT for diagnosing and treating cancer and inflammatory conditions -
XX
PS Claim 1; Page 193; 210pp; English.
XX
CC The invention relates to a human cytokine receptor polypeptide,
CC designated zcytor16. The zcytor16 polypeptide can be expressed by
CC standard recombinant methodology and can bind to IL-TIF (undefined). The
CC zcytor16 protein is useful for: inhibiting IL-TIF induced proliferation
CC or differentiation of hematopoietic cell(s) (progenitors); reducing
CC IL-TIF induced or IL-9 induced inflammation; and suppressing an
CC inflammatory response in a mammal with inflammation. Heteromeric/
CC multimeric receptor polypeptides such as soluble zcytor 16/CRF2-4 can be
CC used to reduce progression and symptoms of cancer. Zcytor16 polypeptides
CC can also be used to detect IL-TIF levels which is indicative of
CC pathological conditions including inflammatory states (e.g. rheumatoid
CC arthritis) and cancer. Antibodies that bind zcytor16 polypeptides and the
CC polypeptides themselves are useful for the treatment of inflammation,
CC inflammatory diseases (e.g. infection, asthma, inflammatory bowel
CC disease, rheumatoid arthritis and atherosclerosis) and autoimmune
CC diseases. The antibodies and zcytor16 polynucleotides are also useful
CC for detecting cancer. The present sequence represents the human zcytor16
CC extracellular domain fragment.
XX
SQ Sequence 210 AA;

Query Match 23.0%; Score 263; DB 22; Length 210;
Best Local Similarity 34.0%; Pred. No. 2.6e-21;
Matches 66; Conservative 29; Mismatches 87; Indels 12; Gaps 4;

Qy 9 QHVKFQSSNFENILTWDSGPEGTPD-TVYSIEYKTYGERDWVAKKGCQRITRKSCNLTVE 67
Db 11 QRVQFQSRNFHNILQWQPGRALTGNSSVYFVQYKIYGQRQWKNKEDCWGTQELSCDLTSE 70

Qy 68 TGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQMIVHPTPT 127
Db 71 TSDIQEPYYGRVRAASAGSYSEWSMTPRFTPWWETKIDPPVMNITQVNGSLLVILHAPNL 130

Qy 128 PIRAGDGHRLTLEDIFHDLFYHLELQVN------RTYQMHLGGKQREYEFFGLTPDTEFL 181
Db 131 PYRYQKEKNVSIED-YYELLYRVFIINNSLEKEQKVYE----GAHRAVEIEALTPHSSYC 185

Qy 182 GTIMICVPTWAKES 195
Db 186 VVAEIYQPMLDRRS 199

RESULT 15
AAE17319
ID AAE17319 standard; Protein; 214 AA.
XX
AC AAE17319;
XX
DT 18-APR-2002 (first entry)
XX
DE Human cytokine receptor protein, sbg456548CytoRa #1.
XX
KW Human; therapy; wound healing disorder; vaccine; cancer; infection;
KW autoimmune disorder; haematopoietic disorder; inflammation; arthritis;
KW Parkinson's disease; Huntington's chorea; schizophrenia; antiarrhythmic;
KW multiple sclerosis; Alzheimer's disease; analgesic; cardiant; asthma;
KW ischaemia; stroke; AIDS; bone disease; atherosclerosis; brain disorder;
KW depression; cardiovascular disease; myocardial infarction; renal failure;
KW respiratory disease; liver disorder; Panconi's syndrome; spleen disorder;
KW type II diabetes mellitus; skeletal muscle disorder; immunosuppressive;
KW hypersplenism; renal disease; hypoglycaemia; gastrointestinal disease;
KW nootropic; cirrhosis; Hodgkin's disease; neuroleptic; antiinflammatory;
KW haemostatic; vulnerary; anticonvulsant; antirheumatic; neuroprotective;
KW nephrotropic; hypotensive; vasotropic; cytostatic; cerebroprotective;
KW allergy; cytokine receptor.
XX
OS Homo sapiens.
XX
PN WO200198342-A1.
XX
PD 27-DEC-2001.
XX
PF 22-JUN-2001; 2001WO-US19929.
XX
PR 22-JUN-2000; 2000US-213156P.
PR 22-JUN-2000; 2000US-213161P.
XX

PA (SMIK) SMITHKLINE BEECHAM CORP.
PA (SMIK) SMITHKLINE BEECHAM PLC.
PA (GLAX) GLAXO GROUP LTD.
XX
PI Agarwal P, Cogswell JP, Kabnic KS, Lai Y, Martensen SA;
PI Murdock PR, Smith RF, Strum JC, Xiang Z, Xie Q, Rizni SK;
XX
DR WPI; 2002-139783/18.
DR N-PSDB; AAD27814.
XX
PT Novel secreted and membrane-associated polypeptides and polynucleotides
PT useful for preventing, ameliorating or correcting dysfunction or
PT disease including diabetes, cancer, hypertension and growth
PT abnormalities -
XX
PS Claim 1; Page 122; 138pp; English.
XX
CC The invention relates to secreted and membrane-associated polypeptides
CC and polynucleotides. The sequences of the invention are useful in
CC diagnostic assays for detecting diseases associated with inappropriate
CC activity or levels of these polynucleotides, and in identifying their
CC agonists and antagonists that are potentially useful in therapy. The
CC sequences of the invention are useful as vaccines for inducing
CC immunological response. The sequences of the invention are useful for
CC treating cancers, infections, autoimmune disorders, haematopoietic
CC disorders, wound healing disorders, cholesteryl ester storage disease,
CC inflammation, congenital muscular dystrophy, junctional epidermolysis
CC bullosa, Parkinson's disease, Huntington's chorea, multiple sclerosis,
CC viral and bacterial infections, Alzheimer's disease, asthma, arthritis,
CC allergies, schizophrenia, sbg442445PROa-associated disorders,
CC septicaemia, psoriasis, inflammatory bowel disease, transplant rejection,
CC graft verse host disease, ischaemia, stroke, acute respiratory disease
CC syndrome, restenosis, brain injury, AIDS, bone diseases, atherosclerosis,
CC brain disorders including parasupranuclear palsy, myotonic dystrophy,
CC depression, anxiety disorders and sleep disorders, cardiovascular
CC diseases including congestive heart failure and myocardial infarction,
CC respiratory diseases including chronic obstructive pulmonary disease,
CC acute bronchitis and adult respiratory distress syndrome, liver disorders
CC including hypercholesterolaemia, hypertriglyceridaemia, cirrhosis, viral
CC and non-viral hepatitis, type II diabetes mellitus, renal disease
CC including acute and chronic renal failure, glomerulonephritis, Fanconi's
CC syndrome, cystinuria, skeletal muscle disorders including hypoglycaemia
CC and tendinitis, gastrointestinal diseases including intestinal
CC obstruction and tropical sprue, spleen disorders including hypersplenism,
CC Hodgkin's disease and malignant lymphoma, testicular cancer, male
CC reproductive diseases including low testosterone and male infertility.
CC The present sequence is human cytokine receptor.
XX
SQ Sequence 214 AA;

Query Match 23.0%; Score 263; DB 23; Length 214;
Best Local Similarity 34.0%; Pred. No. 2.7e-21;
Matches 66; Conservative 29; Mismatches 87; Indels 12; Gaps 4;

```
Qy       9 QHVKFQSSNFENILTWDSGPEGTPD-TVYSIEYKTYGERDWVAKKGCQRITRKSCNLTVE 67
           | |:||| || ||| |  |    | : :|| ::|| ||:| |  |: |      ||:|| |
Db      15 QRVQFQSRNFHNILQWQPGRALTGNSSVYFVQYKIYGQRQWKNKEDCWGTQELSCDLTSE 74

Qy      68 TGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQMIVHPTPT 127
           | :: | || || | |||  |   || ||:    | : || :          |: :|:|
Db      75 TSDIQEPYYGRVRAASAGSYSEWSMTPRFTPWWETKIDPPVMNITQVNGSLLVILHAPNL 134

Qy     128 PIRAGDGHRLTLEDIFHDLFYHLELQVN------RTYQMHLGGKQREYEFFGLTPDTEFL 181
           | |       :::|| :::| | : :  |      : |:    |  |  |   ||| : :
Db     135 PYRYQKEKNVSIED-YYELLYRVFIINNSLEKEQKVYE----GAHRAVEIEALTPHSSYC 189

Qy     182 GTIMICVPTWAKES 195
               |  |   : |
Db     190 VVAEIYQPMLDRRS 203
```

Search completed: January 13, 2003, 15:30:55
Job time : 31.223 secs

GenCore version 5.1.3

OM protein - protein search, using sw model

Run on: January 13, 2003, 15:31:40 ; Search time 6.68662 Seconds
(without alignments)
612.211 Million cell updates/sec

Title: US-09-728-911-34
Perfect score: 1142
Sequence: 1 PEDPSDLLQHVKFQSSNFEN.....AKESAPYMCRVKTLPDRTWT 211

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 118974 seqs, 19401057 residues

Total number of hits satisfying chosen parameters: 118974

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_AA:*
1: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep:*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep:*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep:*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep:*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep:*
6: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
7: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep:*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*
9: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep:*
10: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep:*
11: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep:*
12: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep:*
13: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep:*
14: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1142	100.0	211	10	US-09-728-911-34	Sequence 34, Appl
2	1142	100.0	560	9	US-09-912-672A-5	Sequence 5, Appli
3	1142	100.0	574	9	US-09-912-672A-2	Sequence 2, Appli
4	1142	100.0	574	9	US-10-063-547-164	Sequence 164, App
5	1142	100.0	574	10	US-09-728-911-25	Sequence 25, Appl
6	1142	100.0	574	10	US-09-870-574-4	Sequence 4, Appli
7	1142	100.0	574	12	US-10-006-867-164	Sequence 164, App
8	1126	98.6	212	9	US-09-912-672A-6	Sequence 6, Appli
9	691	60.5	353	9	US-09-912-672A-20	Sequence 20, Appl
10	365	32.0	68	9	US-09-912-672A-9	Sequence 9, Appli
11	263	23.0	210	10	US-09-728-911-13	Sequence 13, Appl
12	263	23.0	231	10	US-09-728-911-2	Sequence 2, Appli
13	263	23.0	231	10	US-09-949-192-6	Sequence 6, Appli
14	191.5	16.8	217	10	US-09-746-359A-55	Sequence 55, Appl
15	191.5	16.8	221	10	US-09-746-359A-12	Sequence 12, Appl
16	191.5	16.8	542	9	US-10-028-072-188	Sequence 188, App
17	191.5	16.8	542	12	US-10-052-586-398	Sequence 398, App
18	191.5	16.8	547	10	US-09-746-359A-54	Sequence 54, Appl
19	191.5	16.8	553	10	US-09-746-359A-11	Sequence 11, Appl
20	191.5	16.8	553	10	US-09-949-192-7	Sequence 7, Appli
21	191.5	16.8	571	10	US-09-746-359A-53	Sequence 53, Appl
22	191	16.7	207	10	US-09-746-359A-65	Sequence 65, Appl
23	191	16.7	214	10	US-09-746-359A-63	Sequence 63, Appl
24	191	16.7	559	10	US-09-746-359A-62	Sequence 62, Appl
25	191	16.7	594	10	US-09-746-359A-23	Sequence 23, Appl
26	181	15.8	217	10	US-09-746-359A-38	Sequence 38, Appl
27	181	15.8	514	10	US-09-746-359A-39	Sequence 39, Appl
28	181	15.8	546	10	US-09-746-359A-37	Sequence 37, Appl
29	131.5	11.5	436	10	US-09-240-675-2	Sequence 2, Appli
30	131.5	11.5	557	10	US-09-240-675-4	Sequence 4, Appli
31	128.5	11.3	575	10	US-09-925-300-1672	Sequence 1672, Ap
32	124	10.9	219	10	US-09-355-000-8	Sequence 8, Appli
33	124	10.9	219	10	US-09-355-000-9	Sequence 9, Appli
34	123	10.8	219	10	US-09-355-000-7	Sequence 7, Appli
35	122	10.7	219	10	US-09-355-000-10	Sequence 10, Appl
36	119	10.4	219	10	US-09-355-000-5	Sequence 5, Appli
37	118	10.3	219	10	US-09-355-000-2	Sequence 2, Appli
38	118	10.3	219	10	US-09-355-000-3	Sequence 3, Appli
39	118	10.3	219	10	US-09-355-000-6	Sequence 6, Appli
40	118	10.3	263	10	US-09-355-000-1	Sequence 1, Appli
41	118	10.3	295	10	US-09-103-067-20	Sequence 20, Appl
42	118	10.3	295	10	US-09-949-192-3	Sequence 3, Appli
43	116	10.2	219	10	US-09-355-000-4	Sequence 4, Appli
44	114.5	10.0	150	10	US-09-746-359A-66	Sequence 66, Appl
45	114.5	10.0	211	10	US-09-728-911-36	Sequence 36, Appl

ALIGNMENTS

RESULT 1
US-09-728-911-34
; Sequence 34, Application US/09728911
; Patent No. US20020012669A1
; GENERAL INFORMATION:
; APPLICANT: Presnell, Scott R.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Kindsvogel, Wayne
; APPLICANT: Chen, Zhi
; TITLE OF INVENTION: Human Cytokine Receptor
; FILE REFERENCE: 99-93
; CURRENT APPLICATION NUMBER: US/09/728,911
; CURRENT FILING DATE: 2000-12-01
; PRIOR APPLICATION NUMBER: US 60/169,049
; PRIOR FILING DATE: 1999-12-03
; PRIOR APPLICATION NUMBER: US 60/232,219
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: US 60/244,610
; PRIOR FILING DATE: 2000-10-31
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 34
; LENGTH: 211
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-728-911-34

Query Match 100.0%; Score 1142; DB 10; Length 211;
Best Local Similarity 100.0%; Pred. No. 8.2e-113;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60

Qy      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120

Qy     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
```

```
Qy    181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
          ||||||||||||||||||||||||||||||||
Db    181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
```

RESULT 2
US-09-912-672A-5
; Sequence 5, Application US/09912672A
; Patent No. US20020164689A1
; GENERAL INFORMATION:
; APPLICANT: Busfield, Samantha J.
; TITLE OF INVENTION: CLASS II CYTOKINE RECEPTOR-LIKE PROTEINS
; TITLE OF INVENTION: AND NUCLEIC ACIDS ENCODING THEM
; FILE REFERENCE: 07334-184001
; CURRENT APPLICATION NUMBER: US/09/912,672A
; CURRENT FILING DATE: 2001-07-23
; PRIOR APPLICATION NUMBER: 09/475,541
; PRIOR FILING DATE: 1999-12-30
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 560
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-912-672A-5

Query Match 100.0%; Score 1142; DB 9; Length 560;
Best Local Similarity 100.0%; Pred. No. 3.1e-112;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      4 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 63

Qy     61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     64 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 123

Qy    121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    124 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 183

Qy    181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
          ||||||||||||||||||||||||||||||||
Db    184 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 214
```

RESULT 3
US-09-912-672A-2
; Sequence 2, Application US/09912672A
; Patent No. US20020164689A1
; GENERAL INFORMATION:
; APPLICANT: Busfield, Samantha J.
; TITLE OF INVENTION: CLASS II CYTOKINE RECEPTOR-LIKE PROTEINS
; TITLE OF INVENTION: AND NUCLEIC ACIDS ENCODING THEM
; FILE REFERENCE: 07334-184001
; CURRENT APPLICATION NUMBER: US/09/912,672A
; CURRENT FILING DATE: 2001-07-23
; PRIOR APPLICATION NUMBER: 09/475,541
; PRIOR FILING DATE: 1999-12-30
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 574
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-912-672A-2

Query Match 100.0%; Score 1142; DB 9; Length 574;
Best Local Similarity 100.0%; Pred. No. 3.2e-112;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 77

Qy     61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     78 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

Qy    121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 197

Qy    181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
          ||||||||||||||||||||||||||||||||
Db    198 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 228
```

RESULT 4
US-10-063-547-164
; Sequence 164, Application US/10063547
; Publication No. US20020182638A1
; GENERAL INFORMATION:
; APPLICANT: Eaton,Dan L.
; APPLICANT: Filvaroff,Ellen
; APPLICANT: Gerritsen,Mary E.
; APPLICANT: Goddard,Audrey
; APPLICANT: Godowski,Paul J.
; APPLICANT: Grimaldi,Christopher J.
; APPLICANT: Gurney,Austin L.
; APPLICANT: Watanabe,Colin K.
; APPLICANT: Wood,William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3230R1C1
; CURRENT APPLICATION NUMBER: US/10/063,547
; CURRENT FILING DATE: 2002-05-02
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 170
; SEQ ID NO 164
; LENGTH: 574
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-063-547-164

Query Match 100.0%; Score 1142; DB 9; Length 574;
Best Local Similarity 100.0%; Pred. No. 3.2e-112;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 77

Qy     61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     78 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

Qy    121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 197

Qy    181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
          ||||||||||||||||||||||||||||||||
Db    198 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 228
```

RESULT 5
US-09-728-911-25
; Sequence 25, Application US/09728911
; Patent No. US20020012669A1
; GENERAL INFORMATION:
; APPLICANT: Presnell, Scott R.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Kindsvogel, Wayne

; APPLICANT: Chen, Zhi
; TITLE OF INVENTION: Human Cytokine Receptor
; FILE REFERENCE: 99-93
; CURRENT APPLICATION NUMBER: US/09/728,911
; CURRENT FILING DATE: 2000-12-01
; PRIOR APPLICATION NUMBER: US 60/169,049
; PRIOR FILING DATE: 1999-12-03
; PRIOR APPLICATION NUMBER: US 60/232,219
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: US 60/244,610
; PRIOR FILING DATE: 2000-10-31
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 25
; LENGTH: 574
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-728-911-25

Query Match 100.0%; Score 1142; DB 10; Length 574;
Best Local Similarity 100.0%; Pred. No. 3.2e-112;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 77

Qy      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      78 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

Qy     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 197

Qy     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
          |||||||||||||||||||||||||||||||
Db     198 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 228
```

RESULT 6
US-09-870-574-4
; Sequence 4, Application US/09870574
; Patent No. US20020102723A1
; GENERAL INFORMATION:
; APPLICANT: Gurney,Austin L.
; APPLICANT: Aggarwal,Sudeepta
; APPLICANT: Xie,Ming-Hong
; APPLICANT: Maruoka,Ellen M.
; APPLICANT: Foster,Jessica S.
; APPLICANT: Goddard,Audrey
; APPLICANT: Wood,William I.
; TITLE OF INVENTION: INTERLEUKIN-22 POLYPEPTIDES, NUCLEIC ACIDS ENCODING
; TITLE OF INVENTION: THE SAME AND METHODS FOR THE TREATMENT OF PANCREATIC DISORDERS
; FILE REFERENCE: P2806-1(US)
; CURRENT APPLICATION NUMBER: US/09/870,574
; CURRENT FILING DATE: 2001-05-30
; PRIOR APPLICATION NUMBER: US 60/169,495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: PCT/US00/14042
; PRIOR FILING DATE: 2000-05-22
; PRIOR APPLICATION NUMBER: PCT/US00/23328
; PRIOR FILING DATE: 2000-08-24
; NUMBER OF SEQ ID NOS: 7
; SEQ ID NO 4
; LENGTH: 574
; TYPE: PRT
; ORGANISM: Homo Sapien
US-09-870-574-4

Query Match 100.0%; Score 1142; DB 10; Length 574;
Best Local Similarity 100.0%; Pred. No. 3.2e-112;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 77

Qy      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      78 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

Qy     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 197

Qy     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
          |||||||||||||||||||||||||||||||
Db     198 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 228
```

RESULT 7
US-10-006-867-164
; Sequence 164, Application US/10006867
; Patent No. US20020119130A1
; GENERAL INFORMATION:
; APPLICANT: Eaton,Dan L.
; APPLICANT: Filvaroff,Ellen
; APPLICANT: Gerritsen,Mary E.
; APPLICANT: Goddard,Audrey
; APPLICANT: Godowski,Paul J.
; APPLICANT: Grimaldi,Christopher J.
; APPLICANT: Gurney,Austin L.
; APPLICANT: Watanabe,Colin K.
; APPLICANT: Wood,William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3230R1C1
; CURRENT APPLICATION NUMBER: US/10/006,867
; CURRENT FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: 60/063435
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/064215
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/082797
; PRIOR FILING DATE: 1998-04-22
; PRIOR APPLICATION NUMBER: 60/083495
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088740
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088811
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088825
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088863
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17

; PRIOR APPLICATION NUMBER: 60/089952
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/090246
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090444
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090688
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090696
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090862
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091628
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/096012
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/096757
; PRIOR FILING DATE: 1998-08-17
; PRIOR APPLICATION NUMBER: 60/096949
; PRIOR FILING DATE: 1998-08-18
; PRIOR APPLICATION NUMBER: 60/096959
; PRIOR FILING DATE: 1998-08-18
; PRIOR APPLICATION NUMBER: 60/097954
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/097971
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/097979
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/099741
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099763
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099792
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099815
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100662
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100683
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100684
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100930
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101279
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: 60/101475
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101743
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/102570
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/103449
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103678
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103679
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103711
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/105000
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105002
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105881
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106030
; PRIOR FILING DATE: 1998-10-28
; PRIOR APPLICATION NUMBER: 60/106464
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/106856
; PRIOR FILING DATE: 1998-11-03
; PRIOR APPLICATION NUMBER: 60/108807
; PRIOR FILING DATE: 1998-11-17
; PRIOR APPLICATION NUMBER: 60/112419
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/112422
; PRIOR FILING DATE: 1998-12-15
; PRIOR APPLICATION NUMBER: 60/112853
; PRIOR FILING DATE: 1998-12-16
; PRIOR APPLICATION NUMBER: 60/113011
; PRIOR FILING DATE: 1998-12-16
; PRIOR APPLICATION NUMBER: 60/112854
; PRIOR FILING DATE: 1998-12-16
; PRIOR APPLICATION NUMBER: 60/113300
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113408
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/113430
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/113621
; PRIOR FILING DATE: 1998-12-23
; PRIOR APPLICATION NUMBER: 60/114223
; PRIOR FILING DATE: 1998-12-30
; PRIOR APPLICATION NUMBER: 60/115614
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/116527
; PRIOR FILING DATE: 1999-01-20
; PRIOR APPLICATION NUMBER: 60/116843
; PRIOR FILING DATE: 1999-01-22
; PRIOR APPLICATION NUMBER: 60/119285
; PRIOR FILING DATE: 1999-02-09
; PRIOR APPLICATION NUMBER: 60/119287
; PRIOR FILING DATE: 1999-02-09
; PRIOR APPLICATION NUMBER: 60/119525
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/119549
; PRIOR FILING DATE: 1999-02-10
; PRIOR APPLICATION NUMBER: 60/120014
; PRIOR FILING DATE: 1999-02-11
; PRIOR APPLICATION NUMBER: 60/129122
; PRIOR FILING DATE: 1999-04-13
; PRIOR APPLICATION NUMBER: 60/129674
; PRIOR FILING DATE: 1999-04-16
; PRIOR APPLICATION NUMBER: 60/131291
; PRIOR FILING DATE: 1999-04-27
; PRIOR APPLICATION NUMBER: 60/138387
; PRIOR FILING DATE: 1999-06-09
; PRIOR APPLICATION NUMBER: 60/144791
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/169495
; PRIOR FILING DATE: 1999-12-07
; PRIOR APPLICATION NUMBER: 60/175481
; PRIOR FILING DATE: 2000-01-11
; PRIOR APPLICATION NUMBER: 60/191007
; PRIOR FILING DATE: 2000-03-21
; PRIOR APPLICATION NUMBER: 60/199397
; PRIOR FILING DATE: 2000-04-25
; PRIOR APPLICATION NUMBER: 09/380139
; PRIOR FILING DATE: 1998-08-25
; PRIOR APPLICATION NUMBER: 09/311832
; PRIOR FILING DATE: 1999-05-14
; PRIOR APPLICATION NUMBER: 09/380137
; PRIOR FILING DATE: 1999-08-25
; PRIOR APPLICATION NUMBER: 09/380138
; PRIOR FILING DATE: 1999-08-25

```
;  PRIOR APPLICATION NUMBER: 09/380142

  Query Match             100.0%;  Score 1142;  DB 12;  Length 574;
  Best Local Similarity   100.0%;  Pred. No. 3.2e-112;
  Matches  211;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      18 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 77

Qy      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      78 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 137

Qy     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     138 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 197

Qy     181 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 211
          |||||||||||||||||||||||||||||||
Db     198 LGTIMICVPTWAKESAPYMCRVKTLPDRTWT 228


RESULT 8
US-09-912-672A-5
; Sequence 6, Application US/09912672A
; Patent No. US20020164689A1
; GENERAL INFORMATION:
;  APPLICANT: Busfield, Samantha J.
;  TITLE OF INVENTION: CLASS II CYTOKINE RECEPTOR-LIKE PROTEINS
;  TITLE OF INVENTION:  AND NUCLEIC ACIDS ENCODING THEM
;  FILE REFERENCE: 07334-184001
;  CURRENT APPLICATION NUMBER: US/09/912,672A
;  CURRENT FILING DATE:  2001-07-23
;  PRIOR APPLICATION NUMBER: 09/475,541
;  PRIOR FILING DATE: 1999-12-30
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 6
;   LENGTH: 212
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-912-672A-6

  Query Match             98.6%;  Score 1126;  DB 9;  Length 212;
  Best Local Similarity   100.0%;  Pred. No. 4e-111;
  Matches  209;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       4 PEDPSDLLQHVKFQSSNFENILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRK 63

Qy      61 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      64 SCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQM 123

Qy     121 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     124 IVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQREYEFFGLTPDTEF 183

Qy     181 LGTIMICVPTWAKESAPYMCRVKTLPDRT 209
          |||||||||||||||||||||||||||||
Db     184 LGTIMICVPTWAKESAPYMCRVKTLPDRT 212


RESULT 9
US-09-912-672A-20
; Sequence 20, Application US/09912672A
; Patent No. US20020164689A1
; GENERAL INFORMATION:
;  APPLICANT: Busfield, Samantha J.
;  TITLE OF INVENTION: CLASS II CYTOKINE RECEPTOR-LIKE PROTEINS
;  TITLE OF INVENTION:  AND NUCLEIC ACIDS ENCODING THEM
;  FILE REFERENCE: 07334-184001
;  CURRENT APPLICATION NUMBER: US/09/912,672A
;  CURRENT FILING DATE:  2001-07-23
;  PRIOR APPLICATION NUMBER: 09/475,541
;  PRIOR FILING DATE: 1999-12-30
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 20
;   LENGTH: 353
;   TYPE: PRT
;   ORGANISM: Mus musculus
US-09-912-672A-20

  Query Match             60.5%;  Score 691;  DB 9;  Length 353;
  Best Local Similarity   78.5%;  Pred. No. 5e-65;
  Matches  128;  Conservative   13;  Mismatches   22;  Indels    0;  Gaps    0;

Qy      48 WVAKKGCQRITRKSCNLTVETGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPP 107
           |:|| |||||:| ||||:|| | || |||:||||||||   ||||||||||||||:|||
Db       1 WLAKAGCQRITQKFCNLTMETRNHTEFYYAKVTAVSAGGPPVTKMTDRFSSLQHTTIKPP 60

Qy     108 DVTCISKVRSIQMIVHPTPTPIRAGDGHRLTLEDIFHDLFYHLELQVNRTYQMHLGGKQR 167
           ||||| |||||||:|||| ||: : |||:||||:||||||| ||| || |||||| ||||
Db      61 DVTCIPKVRSIQMLVHPTLTPVLSEDGHQLTLEEIFHDLFYRLELHVNHTYQMHLEGKQR 120

Qy     168 EYEFFGLTPDTEFLGTIMICVPTWAKESAPYMCRVKTLPDRTW 210
           |||| ||||||||||:| |  |  :||||||:||||||||||
Db     121 EYEFLGLTPDTEFLGSITILTPILSKESAPYVCRVKTLPDRTW 163


RESULT 10
US-09-912-672A-9
; Sequence 9, Application US/09912672A
; Patent No. US20020164689A1
; GENERAL INFORMATION:
;  APPLICANT: Busfield, Samantha J.
;  TITLE OF INVENTION: CLASS II CYTOKINE RECEPTOR-LIKE PROTEINS
;  TITLE OF INVENTION:  AND NUCLEIC ACIDS ENCODING THEM
;  FILE REFERENCE: 07334-184001
;  CURRENT APPLICATION NUMBER: US/09/912,672A
;  CURRENT FILING DATE:  2001-07-23
;  PRIOR APPLICATION NUMBER: 09/475,541
;  PRIOR FILING DATE: 1999-12-30
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 9
;   LENGTH: 68
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-912-672A-9

  Query Match             32.0%;  Score 365;  DB 9;  Length 68;
  Best Local Similarity   100.0%;  Pred. No. 1.1e-31;
  Matches   68;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      21 ILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRKSCNLTVETGNLTELYYARVT 80
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 ILTWDSGPEGTPDTVYSIEYKTYGERDWVAKKGCQRITRKSCNLTVETGNLTELYYARVT 60

Qy      81 AVSAGGRS 88
           ||||||||
Db      61 AVSAGGRS 68


RESULT 11
US-09-728-911-13
; Sequence 13, Application US/09728911
; Patent No. US20020012669A1
; GENERAL INFORMATION:
;  APPLICANT:  Presnell, Scott R.
;  APPLICANT:  Xu, Wenfeng
;  APPLICANT:  Kindsvogel, Wayne
;  APPLICANT:  Chen, Zhi
```

```
;  TITLE OF INVENTION:  Human Cytokine Receptor
;  FILE REFERENCE:  99-93
;  CURRENT APPLICATION NUMBER: US/09/728,911
;  CURRENT FILING DATE:  2000-12-01
;  PRIOR APPLICATION NUMBER:  US 60/169,049
;  PRIOR FILING DATE:  1999-12-03
;  PRIOR APPLICATION NUMBER:  US 60/232,219
;  PRIOR FILING DATE:  2000-09-13
;  PRIOR APPLICATION NUMBER:  US 60/244,610
;  PRIOR FILING DATE:  2000-10-31
;  NUMBER OF SEQ ID NOS:  36
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 13
;   LENGTH: 210
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-728-911-13

  Query Match             23.0%;  Score 263;  DB 10;  Length 210;
  Best Local Similarity   34.0%;  Pred. No. 2.7e-20;
  Matches   66;  Conservative   29;  Mismatches   87;  Indels   12;  Gaps    4;

Qy       9 QHVKFQSSNFENILTWDSGPEGTPD-TVYSIEYKTYGERDWVAKKGCQRITRKSCNLTVE 67
           | |:||| || ||| | |   | : :|| ::|| ||:| |  |: |       ||:|| |
Db      11 QRVQFQSRNFHNILQWQPGRALTGNSSVYFVQYKIYGQRQWKNKEDCWGTQELSCDLTSE 70

Qy      68 TGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQMIVHPTPT 127
           | ::  | || || | |||   |    || ||:    | : || :        |: :|:|
Db      71 TSDIQEPYYGRVRAASAGSYSEWSMTPRFTPWWETKIDPPVMNITQVNGSLLVILHAPNL 130

Qy     128 PIRAGDGHRLTLEDIFHDLFYHLELQVN------RTYQMHLGGKQREYEFFGLTPDTEFL 181
           | |       :::|| :::| | : :  |      : |:    |  |  |   ||| : :
Db     131 PYRYQKEKNVSIED-YYELLYRVFIINNSLEKEQKVYE----GAHRAVEIEALTPHSSYC 185

Qy     182 GTIMICVPTWAKES 195
             |  |   : |
Db     186 VVAEIYQPMLDRRS 199


RESULT 12
US-09-728-911-2
; Sequence 2, Application US/09728911
; Patent No. US20020012669A1
; GENERAL INFORMATION:
;  APPLICANT:  Presnell, Scott R.
;  APPLICANT:  Xu, Wenfeng
;  APPLICANT:  Kindsvogel, Wayne
;  APPLICANT:  Chen, Zhi
;  TITLE OF INVENTION:  Human Cytokine Receptor
;  FILE REFERENCE:  99-93
;  CURRENT APPLICATION NUMBER: US/09/728,911
;  CURRENT FILING DATE:  2000-12-01
;  PRIOR APPLICATION NUMBER:  US 60/169,049
;  PRIOR FILING DATE:  1999-12-03
;  PRIOR APPLICATION NUMBER:  US 60/232,219
;  PRIOR FILING DATE:  2000-09-13
;  PRIOR APPLICATION NUMBER:  US 60/244,610
;  PRIOR FILING DATE:  2000-10-31
;  NUMBER OF SEQ ID NOS:  36
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 2
;   LENGTH: 231
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-728-911-2

  Query Match             23.0%;  Score 263;  DB 10;  Length 231;
  Best Local Similarity   34.0%;  Pred. No. 3.1e-20;
  Matches   66;  Conservative   29;  Mismatches   87;  Indels   12;  Gaps    4;

Qy       9 QHVKFQSSNFENILTWDSGPEGTPD-TVYSIEYKTYGERDWVAKKGCQRITRKSCNLTVE 67
           | |:||| || ||| | |   | : :|| ::|| ||:| |  |: |       ||:|| |
Db      32 QRVQFQSRNFHNILQWQPGRALTGNSSVYFVQYKIYGQRQWKNKEDCWGTQELSCDLTSE 91

Qy      68 TGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQMIVHPTPT 127
           | ::  | || || | |||   |    || ||:    | : || :        |: :|:|
Db      92 TSDIQEPYYGRVRAASAGSYSEWSMTPRFTPWWETKIDPPVMNITQVNGSLLVILHAPNL 151

Qy     128 PIRAGDGHRLTLEDIFHDLFYHLELQVN------RTYQMHLGGKQREYEFFGLTPDTEFL 181
           | |       :::|| :::| | : :  |      : |:    |  |  |   ||| : :
Db     152 PYRYQKEKNVSIED-YYELLYRVFIINNSLEKEQKVYE----GAHRAVEIEALTPHSSYC 206

Qy     182 GTIMICVPTWAKES 195
             |  |   : |
Db     207 VVAEIYQPMLDRRS 220


RESULT 13
US-09-949-192-6
; Sequence 6, Application US/09949192
; Patent No. US20020142292A1
; GENERAL INFORMATION:
;  APPLICANT: Parham, Christi L.
;  APPLICANT:  Gorman, Daniel L.
;  APPLICANT:  Kurata, Hirokazu
;  APPLICANT:  Arai, Naoko
;  APPLICANT:  Sana, Theodore R.
;  APPLICANT:  Mattson, Jeanine D.
;  APPLICANT:  Murphy, Erin E.
;  APPLICANT:  Savkoor, Chetan
;  APPLICANT:  Grein, Jeffery
;  APPLICANT:  Smith, Kathleen M.
;  APPLICANT:  McClanahan, Terrill K.
;  TITLE OF INVENTION: MAMMALIAN GENES; RELATED REAGENTS AND METHODS
;  FILE REFERENCE: DX01169K
;  CURRENT APPLICATION NUMBER: US/09/949,192
;  CURRENT FILING DATE:  2001-09-07
;  PRIOR APPLICATION NUMBER: 60/231,267
;  PRIOR FILING DATE: 2000-09-08
;  NUMBER OF SEQ ID NOS: 53
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
;   LENGTH: 231
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-949-192-6

  Query Match             23.0%;  Score 263;  DB 10;  Length 231;
  Best Local Similarity   34.0%;  Pred. No. 3.1e-20;
  Matches   66;  Conservative   29;  Mismatches   87;  Indels   12;  Gaps    4;

Qy       9 QHVKFQSSNFENILTWDSGPEGTPD-TVYSIEYKTYGERDWVAKKGCQRITRKSCNLTVE 67
           | |:||| || ||| | |   | : :|| ::|| ||:| |  |: |       ||:|| |
Db      32 QRVQFQSRNFHNILQWQPGRALTGNSSVYFVQYKIYGQRQWKNKEDCWGTQELSCDLTSE 91

Qy      68 TGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQMIVHPTPT 127
           | ::  | || || | |||   |    || ||:    | : || :        |: :|:|
Db      92 TSDIQEPYYGRVRAASAGSYSEWSMTPRFTPWWETKIDPPVMNITQVNGSLLVILHAPNL 151

Qy     128 PIRAGDGHRLTLEDIFHDLFYHLELQVN------RTYQMHLGGKQREYEFFGLTPDTEFL 181
           | |       :::|| :::| | : :  |      : |:    |  |  |   ||| : :
Db     152 PYRYQKEKNVSIED-YYELLYRVFIINNSLEKEQKVYE----GAHRAVEIEALTPHSSYC 206

Qy     182 GTIMICVPTWAKES 195
             |  |   : |
Db     207 VVAEIYQPMLDRRS 220


RESULT 14
US-09-746-359A-55
; Sequence 55, Application US/09746359A
; Patent No. US20020042366A1
; GENERAL INFORMATION:
;  APPLICANT: Thompson, Penny
;  APPLICANT:  Foster, Donald C.
;  APPLICANT:  Xu, Wenfeng
```

```
;  APPLICANT:  Madden, Karen L.
;  APPLICANT:  Kelly, James D.
;  APPLICANT:  Sprecher, Cindy A.
;  APPLICANT:  Blumberg, Hal
;  APPLICANT:  Eagan, Maribeth A.
;  APPLICANT:  Jaspers, Stephen R.
;  APPLICANT:  Chandrasekher, Yasmin A.
;  APPLICANT:  No. US20020042366A1ak, Julia E.
;  TITLE OF INVENTION: Method for Treating Inflammation
;  FILE REFERENCE: 99-108
;  CURRENT APPLICATION NUMBER: US/09/746,359A
;  CURRENT FILING DATE:  2001-05-21
;  PRIOR APPLICATION NUMBER: 60/171,969
;  PRIOR FILING DATE: 1999-12-23
;  PRIOR APPLICATION NUMBER: 60/213,341
;  PRIOR FILING DATE: 2000-06-22
;  NUMBER OF SEQ ID NOS: 72
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 55
;   LENGTH: 217
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-746-359A-55

  Query Match             16.8%;  Score 191.5;  DB 10;  Length 217;
  Best Local Similarity   25.6%;  Pred. No. 9.6e-13;
  Matches   55;  Conservative   44;  Mismatches   89;  Indels   27;  Gaps    8;

Qy      10 HVKFQSSNFENILTWDSGPEGTP--DTVYSIEYKTYGERDWVAKKGCQRITRKSCNLTVE 67
           :: | | | :|:| | : |||       |:::|  ||:: |: |  |: | |  |:|: |
Db      13 NITFLSINMKNVLQW-TPPEGLQGVKVTYTVQYFIYGQKKWLNKSECRNINRTYCDLSAE 71

Qy      68 TGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQMIV----- 122
           | :    |||:| |:     |    : ||     | : ||:|   :  :|| :::
Db      72 TSDYEHQYYAKVKAIWGTKCSKWAESGRFYPFLETQIGPPEVALTTDEKSISVVLTAPEK 131

Qy     123 ---HPTPTPIRAGDGHRLTLEDIFHDLFYH---LELQVNRTYQMHLGGKQREYEFFGLTP 176
             :|   |:        ::: |: :| |:   |  : |||:   :           | |
Db     132 WKRNPEDLPV--------SMQQIYSNLKYNVSVLNTKSNRTWSQCV--TNHTLVLTWLEP 181

Qy     177 DTEFLGTIMICVPTWAKESAP--YMCRVKTLPDRT 209
           :| :   :   ||   : : |    |  :|| |::
Db     182 NTLYCVHVESFVPGPPRRAQPSEKQC-ARTLKDQS 215


RESULT 15
US-09-746-359A-12
; Sequence 12, Application US/09746359A
;   Patent No. US20020042366A1
;   GENERAL INFORMATION:
;   APPLICANT: Thompson, Penny
;   APPLICANT:  Foster, Donald C.
;   APPLICANT:  Xu, Wenfeng
;   APPLICANT:  Madden, Karen L.
;   APPLICANT:  Kelly, James D.
;   APPLICANT:  Sprecher, Cindy A.
;   APPLICANT:  Blumberg, Hal
;   APPLICANT:  Eagan, Maribeth A.
;   APPLICANT:  Jaspers, Stephen R.
;   APPLICANT:  Chandrasekher, Yasmin A.
;   APPLICANT:  No. US20020042366A1ak, Julia E.
;   TITLE OF INVENTION: Method for Treating Inflammation
;   FILE REFERENCE: 99-108
;   CURRENT APPLICATION NUMBER: US/09/746,359A
;   CURRENT FILING DATE:  2001-05-21
;   PRIOR APPLICATION NUMBER: 60/171,969
;   PRIOR FILING DATE: 1999-12-23
;   PRIOR APPLICATION NUMBER: 60/213,341
;   PRIOR FILING DATE: 2000-06-22
;   NUMBER OF SEQ ID NOS: 72
;   SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 12
;    LENGTH: 221
;    TYPE: PRT
;    ORGANISM: Homo sapiens
US-09-746-359A-12

  Query Match             16.8%;  Score 191.5;  DB 10;  Length 221;
  Best Local Similarity   25.6%;  Pred. No. 9.9e-13;
  Matches   55;  Conservative   44;  Mismatches   89;  Indels   27;  Gaps    8;

Qy      10 HVKFQSSNFENILTWDSGPEGTP--DTVYSIEYKTYGERDWVAKKGCQRITRKSCNLTVE 67
           :: | | | :|:| | : |||       |:::|  ||:: |: |  |: | |  |:|: |
Db      13 NITFLSINMKNVLQW-TPPEGLQGVKVTYTVQYFIYGQKKWLNKSECRNINRTYCDLSAE 71

Qy      68 TGNLTELYYARVTAVSAGGRSATKMTDRFSSLQHTTLKPPDVTCISKVRSIQMIV----- 122
           | :    |||:| |:     |    : ||     | : ||:|   :  :|| :::
Db      72 TSDYEHQYYAKVKAIWGTKCSKWAESGRFYPFLETQIGPPEVALTTDEKSISVVLTAPEK 131

Qy     123 ---HPTPTPIRAGDGHRLTLEDIFHDLFYH---LELQVNRTYQMHLGGKQREYEFFGLTP 176
             :|   |:        ::: |: :| |:   |  : |||:   :           | |
Db     132 WKRNPEDLPV--------SMQQIYSNLKYNVSVLNTKSNRTWSQCV--TNHTLVLTWLEP 181

Qy     177 DTEFLGTIMICVPTWAKESAP--YMCRVKTLPDRT 209
           :| :   :   ||   : : |    |  :|| |::
Db     182 NTLYCVHVESFVPGPPRRAQPSEKQC-ARTLKDQS 215


Search completed: January 13, 2003, 15:44:36
Job time : 7.68662 secs
```